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https://doi.org/10.1016/j.jacl.2019.02.0BACKGROUND: Evidence on the causal link between plasma triglyceride (TG) levels and risk for
cardiovascular disease (CVD) has recently emerged. Individuals with the metabolic syndrome have
an increased risk for acquiring elevated TG levels later in life. Moreover, common DNA sequence
variations in genes affecting TG levels identify individuals at risk for elevated plasma TG levels.
OBJECTIVE: We evaluated whether a 3-single nucleotide polymorphism (SNP) TG gene risk score
(GRS) and a metabolic risk score (MetRS) both improved CVD risk prediction.
METHODS: A 3-SNP GRS and MetRS were generated in the EPIC-Norfolk cohort (n 5 20,074)
based on 3 SNPs in LPL and APOA5 or the number of Metabolic Syndrome criteria present (maximum
5), respectively. The associations between the 3-SNP GRS, MetRS, TG levels, and CVD risk were
evaluated.
RESULTS: The 3-SNP GRS and MetRS were both linearly associated with plasma TG levels, that
is, 10.25 mmol/L [95% CI 0.22–0.27] per allele change (P , .001) and 10.72 mmol/L [95% CI
0.70–0.73] per increase of number of metabolic syndrome risk score points (P , .001), respectively.
We observed a positive association between the 3-SNP GRS and the risk of CVD with an adjusted haz-
ard ratio (HR) of 1.35 [95% CI 1.04–1.74] for the highest versus the lowest GRS, which was indepen-
dent of the MetRS. For the MetRS, the adjusted HR was 2.03 [95% CI 1.73–2.40] for the highest versus
the lowest MetRS.o the manuscript.
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Hypertriglyceridemia, that is, an elevated plasma level
of triglycerides (TG), is a trait that is influenced by
numerous factors like lifestyle, environmental factors, and
genetic predisposition. The importance of TG for cardio-
vascular disease (CVD) risk estimation has emerged since
2007 from large epidemiological studies, genetic studies,
and clinical trials, showing a consistent and robust associ-
ation.1–10 TGs are derived from dietary sources or from
direct hepatic de novo lipogenesis. Exogenous TG is trans-
ported in apo-B48–containing chylomicron particles that
undergo a rapid hepatic catabolism. Apo B-100–containing
VLDL particles of hepatic origin are the major circulating
TG-carrying lipoproteins that on entering the circulation
undergo rapid lipoprotein lipase (LPL)-mediated lipolysis
allowing free fatty acid uptake in tissues for energy use
or storage, which eventually results in the generation of
cholesterol-rich LDL particles. In the presence of reduced
LPL-mediated lipolysis, elevated fasting plasma TG levels
are a marker for the presence of increased circulating
cholesterol- and TG-enriched apo-B100–containing
remnant particles, that is, very low density and intermediate
density lipoproteins that are associated with increased risk
for CVD.11–15
Over the years, several common single nucleotide poly-
morphisms (SNPs) with significant effects on plasma TG
levels have been identified, including genetic variants in
lipoprotein lipase (LPL) and apolipoprotein A-V
(APOA5).16–18 Subsequently, genome-wide association
studies (GWAS) were able to replicate these findings and
identify additional loci, such as those encoding for tribbles
pseudokinase 1(TRIB1), glucokinase regulator (GCKR),
and angiopoietin-like protein 4 (ANGPTL4), thereby stress-
ing the polygenic nature of plasma TG levels.4,19–28 It has
been shown that loss of function variants in APOC3 results
in decreased risk for CHD as shown in 2 large population
cohorts.29–32 Thus, Mendelian randomization studies sup-
port the concept that the association between TG levels
and CVD risk exists, however, causality remains to be as-
sessed.33–36
Elevated plasma TG levels are frequently observed in
metabolic syndrome patients,37 besides other metabolic ab-
normalities such as low high-density lipoprotein cholesterol
(HDL-C), hypertension, obesity, and type 2 diabetes melli-
tus. However, hypertriglyceridemia may additionally occur
because of the presence of loss of function variations in
genes that play an essential role in TG metabolism.36 A
similar observation has been met with regard to the pres-
ence of elevated plasma low-density lipoprotein cholesterol(LDL-C) levels. Genetically determined low levels of LDL-
C were shown to be more strongly associated with low car-
diovascular disease (CVD) risk than short-term statin-medi-
ated lowering of plasma LDL-C levels.38
We hypothesize that a 3-SNP gene risk score (GRS)
based on genetic variants influencing plasma TG will be
associated with increased risk for CHD. In the present
study, we set out to test which variants should be used in a
3-SNP GRS. Next, we investigated the relationship of the
3-SNP GRS and a clinically derived metabolic risk score
(MetRS) as risk factors for CVD in the European Prospec-
tive Investigation of Cancer (EPIC)-Norfolk prospective
population study.Methods
Study design
The EPIC-Norfolk prospective population study con-
sists of 25,639 individuals recruited from general prac-
tices in the Norfolk area, United Kingdom.39 Study
participants aged between 39 and 79 years were enrolled
between 1993 and 1997. At baseline, patients completed
general health and lifestyle questionnaires. During
follow-up, all participants were flagged for mortality at
the UK Office of National Statistics, and vital status
was ascertained for the entire cohort. Data on all hospital
contacts throughout England and Wales were obtained us-
ing National Health Service numbers through linkage
with the East Norfolk Health Authority (ENCORE) data-
base. Hospital records and death certificates were coded
by trained nosologists and categorized according to the
International Classification of Disease 10th (ICD-10)
revision. Death or hospitalizations were attributed to an
outcome if the corresponding ICD-10 code was recorded
as the underlying cause. The study protocol was approved
by the Norwich District Health Authority Ethics Commit-
tee. All participants gave written informed consent. In the
complete EPIC-Norfolk cohort, DNA-SNP data were
available for n 5 20,074 individuals.
In 2004, a prospective case-control substudy was
designed including participants of the EPIC-Norfolk study.
Cases were people who developed CAD during follow-up
until 2003. Control participants remained free of any CVD
during an average of 7.4 years of follow-up. The controls
were matched to each case by sex and age.40 In this sub-
study, DNA from n 5 2649 participants (2132 controls
and n 5 2105 cases) was available for further analyses as
well as plasma samples for in depth phenotyping.
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Nonfasting blood samples were taken by venipuncture in
EDTA-containing vacutainers at the baseline clinic visit
and processed at the Department of Clinical Biochemistry,
University of Cambridge (UK), where all lipids assays were
performed.41 Plasma was isolated by centrifugation for
15 minutes, 3000 rpm, 4C, and stored at 280C for future
analysis. Circulating levels of total cholesterol, HDL-C,
and TG were measured on fresh samples with the RA
1000 (Bayer Diagnostics, Basingstoke, United Kingdom),
and LDL-C levels were calculated with the Friedewald for-
mula.42 Non-HDL cholesterol was calculated by subtract-
ing HDL-C from total cholesterol. Apo B was measured
by using rate immunonephelometry (Behring Nephelom-
eter BNII, Marburg, Germany).43 HbA1c was measured
using Diamat ion exchange HPLC (Bio-Rad Laboratories,
Hemel Hempstead, United Kingdom).39
In the case-control subset, additional parameters were
tested. Lipoprotein particle size and particle number was
analyzed with an automated nuclear magnetic resonance
(NMR) spectroscopy by Liposcience Co as described.44
Plasma LPL mass and Apo A-V were measured as
described.16 Samples were analyzed in random order to
avoid systemic bias. Researchers and laboratory personnel
had no access to identifiable information and could identify
samples by number only.
SNP selection and genotyping on the case/
control cohort
We selected SNPs based on their association with
elevated plasma TG levels. A number of different sources
were used: (1) leading SNPs significantly associated with
plasma TG levels identified in a large GWAS study (LPL
and APOA5),28 (2) common SNPs, which were originally
published in association studies (LPL, APOA5, APOA4,
ANGPTL4, GALNT2, APOC3, GCKR, TRIB1)20,28,45–48,
and (3) common variants at the APOC2, LMF1, and
GPIHBP1 loci that repeatedly show no significant associa-
tion with plasma TG in large GWAS.20,45–48 Patients with
complete loss of function mutations in these 3 genes suffer
from a monogenic form of severe hypertriglyceridemia,
resembling complete or partial LPL deficiency. No data
are available to date that show the influence of common ge-
netic variants in these genes and the effect on plasma TG
levels in the general population.48 Tagging SNPs were
selected as described previously using the public available
Hapman program.40 Genotyping was performed using
allelic discrimination with VIC- and FAM-labeled probes
designed by Applied Biosystems (Thermo Fisher Scientific
Inc, Waltham, MA). PCR conditions were denaturation for
10 min at 95C, followed by 40 cycles (30 sec 92C, 45 sec
60C) and run on a CFX PCR system (BioRad Laboratories
Inc, CA). Taqman PCR assay mix was obtained from
Applied Biosystems (Thermo Fisher Scientific Inc, Wal-
tham, MA). All SNPs were initially determined in therandom case-control subset of the cohort (n 5 2649).
SNPs that were significantly associated with plasma TG
levels (P , .05) were selected and tested in a backward
elimination model to explore which SNPs appeared to drive
the association with plasma TG levels. The SNPs, which
remain associated with plasma TG levels, were used to
create the 3-SNP GRS. For each TG-raising allele 1 point
was given. Genotyping in the complete cohort was per-
formed using the GeneChip Human Mapping 500K Array
Set from Affymetrix (Santa Clara, CA).
Metabolic risk score (MetRS)
The presence and severity of the metabolic syndrome
was determined according to the harmonized criteria for the
metabolic syndrome.49 To meet the threshold for metabolic
syndrome, participants had to present with 3 or more of the
following conditions: (1) waist circumference $94 cm for
men or $80 cm for women, (2) TG $ 150 mg/dL
(1.7 mmol/L), (3) HDL-C ,40 mg/dL (1.03 mmol/L) in
men or ,50 mg/dL (1.29 mmol/L) in women, (4) systolic
blood pressure $130 mmHg, diastolic blood pressure
$85, or treatment for hypertension, and/or (5) fasting
plasma glucose $100 mg/dL (5.6 mmol/L) or previously
diagnosed type 2 diabetes. Because fasting plasma glucose
levels were not available in the cohort, HbA1c was chosen
as a surrogate for fasting plasma glucose, with a cutoff of
$5.6%.50 A composite MetRS was generated based on
the presence of the number of metabolic syndrome criteria.
Cardiovascular outcomes definition
For cardiovascular outcomes, the definition of the ACC/
AHAwas used, which included fatal or nonfatal myocardial
infarction or coronary heart disease (CHD) or fatal or
nonfatal stroke.51 A composite of the following ICD-10 co-
des: I20-25 and I60-69 was assessed. As no ICD-10 defini-
tion of stroke was reported in the guideline, the definition
previously used by the AHA (comprising ICD-10 codes
I60-69) was used.52
Statistical analysis
The MetRS was calculated for all people in the complete
cohort. The relationship between single SNPs and plasma
TG levels was assessed by a linear regression model.
Variables with skewed distribution were log-transformed
before being used as continuous variables in statistical
analyses. Associations between GRS and plasma lipid
parameters were calculated using linear regression for
continuous variables and the chi-square test for trend for
categorical variables. To estimate the relative risk of CVD,
a Cox proportional hazards model was used to calculate
hazard ratios (HRs) and 95% confidence intervals for the
GRS, using the lowest TG GRS as the reference category.
For the GRS, multivariable adjustment was used, correcting
for age, sex, BMI, diabetes, smoking status, and
Table 1 Plasma triglyceride concentration according to triglyceride-related SNPs
Gene SNP N GT TG (mmol/L)
GRS points
per SNP
mmol/L TG increase
per allel P* P†
APOA5 rs3135506 17,555 CC 1.50 (1.10–2.20) 0 0.28 ,.001 ,.001
2432 CG 1.70 (1.20–2.50) 1
87 GG 1.90 (1.40–3.30) 2
APOA5 rs662799 17,918 AA 1.50 (1.10–2.20) 0 0.29 ,.001 ,.001
2077 AG 1.70 (1.20–2.50) 1
79 GG 1.80 (1.20–3.10) 2
LPL rs328 16,095 CC 1.60 (1.10–2.30) 2 0.19 ,.001 ,.001
3762 CG 1.40 (1.00–2.00) 1
217 GG 1.30 (0.90–1.90) 0
Number of individuals (N) and triglyceride serum concentrations according to polymorphism are presented as median and 25th and 75th percentile.
GRS point were used for the calculation of the total 3-SNP GRS.
GRS5 gene risk score; GT5 genotype; P*5 unadjusted P-value, P†5 P-value adjusted for age, sex, waist, body mass index, and diabetes. Published
frequency of the SNPs: rs3135506: 0.067; rs662799: 0.8997; rs328: 0.094.
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using the group with without the metabolic syndrome as the
reference category. Multivariable adjustment was used,
correcting for age, sex, and smoking.
HRs for CVD were calculated for participants with
respect to their 3-SNP GRS, stratified for the presence or
absence of the metabolic syndrome (MetRS $3/5,
MetRS #2/5, respectively). The category with a 3-SNP
GRS of 0/6 and a MetRS of #2/5 was used as the
reference category. A probability value of ,0.05 was
considered statistically significant. All statistical ana-
lyses were performed using SPSS (Version 21.0, IBM
Corporation, Armonk, NY).Results
Selection of SNPs for GRS
We determined leading GWAS SNPs in TRIB1, GCKR,
APOA5, LPL, APOC2, APOC3, known missense variantsTable 2 Demographic and lifestyle parameters of individuals accord
3-SNP GRS 0/6 1/6
N 157 2971
Men, n (%) 78 (50%) 1381 (46%)
Age, y 59.5 6 9.3 59.0 6 9.3
Body mass index, kg/m2 26.4 6 3.7 26.3 6 3.8
Waist circumference, cm 88.5 6 11.8 88.4 6 12.5
Current smoker, n (%) 16 (10.3) 325 (11.1)
Diabetes mellitus, n (%) 4 (2.6) 59 (2.0)
Systolic blood pressure, mmHg 136 6 18 135 6 18
Diastolic blood pressure, mmHg 82 6 11 82 6 11
Mean MetRS 0.32 0.43
Data are presented as number (percentage), mean 6 SD.
MetRS 5 metabolic risk score, 3-SNP GRS 5 3-single nucleotide polymorphin ANGPTL4 and APOA4 and tagSNPs in LMF1 and
GPIHBP1 in a random subset of the EPIC-Norfolk cohort
(n 5 2649). The biochemical characteristics of the subset
case-control cohort are presented in Table S2. A higher
BMI and a worsened lipid profile were present in the cases
as compared to the age-matched controls. Details of all
SNPs are documented in Table S1. We did not find any as-
sociations between genetic variations in LMF1, APOC2,
APOA4, GCKR, APOC3, GALNT2, or GPIHBP1 and
plasma TG levels. The SNPs in ANGPTL4 (rs1044250,
rs116843064), TRIB1 (rs2954029), LPL (rs328,
rs12678919), and APOA5 (rs75423577, rs3135506,
rs662799) were all significantly associated with plasma
TG levels with P values varying from ,.05 to ,.001
(Table S3). To explore which SNPs appear to drive the as-
sociation with plasma TG levels, we used backward elimi-
nation in a model that included the 8 SNPs that were
associated with plasma TG levels. Only 3 SNPs remained
significantly associated with plasma TG levels (rs3135506
and rs662799 in APOA5 and rs328 in LPL) and were there-
fore selected to generate the 3-SNP GRS (Table S3). Theing to the 3-SNP GRS
2/6 3/6 $4/6 P
13,284 3394 268
6203 (47%) 1584 (47%) 124 (46%) .96
59.2 6 9.3 59.0 6 9.3 58.7 6 9.2 .41
26.3 6 3.8 26.3 6 3.8 26.3 6 3.9 .98
88.3 6 12.3 88.4 6 12.2 87.3 6 12.1 .75
1534 (11.6) 374 (11.1) 33 (12.4) .86
279 (2.1) 88 (2.6) 8 (3.0) .34
135 6 18 135 6 18 138 6 19 .15
82 6 11 83 6 11 84 6 11 .10
0.49 0.57 0.68
ism gene risk score.
Table 3 Distribution of plasma lipids according to the 3-SNP GRS
3-SNP GRS 0/6 1/6 2/6 3/6 $4/6 R P* P†
Participants,
n (%)
157 (0.8) 2971 (14.8) 13,284 (66.2) 3394 (16.9) 268 (1.3)
Triglyceride,
mmol/l
1.30 (0.90–1.90) 1.40 (1.00–2.00) 1.50 (1.10–2.20) 1.70 (1.20–2.50) 2.10 (1.30–3.20) 0.143 ,.001 ,.001
Total cholesterol,
mmol/L
6.12 6 1.02 6.12 6 1.13 6.16 6 1.14 6.27 6 1.24 6.46 6 1.37 0.046 ,.001 ,.001
HDL-cholesterol,
mmol/L
1.58 6 0.39 1.48 6 0.42 1.41 6 0.42 1.38 6 0.47 1.27 6 0.36 20.080 ,.001 ,.001
LDL-cholesterol,
mmol/L
3.87 6 0.92 3.92 6 1.01 3.95 6 1.02 4.01 6 1.08 4.11 6 1.14 0.028 ,.001 ,.001
Non-HDL-
cholesterol,
mmol/L
4.50 6 1.08 4.62 6 1.14 4.71 6 1.15 4.83 6 1.24 5.05 6 1.27 0.062 ,.001 ,.001
Lipoprotein(a),
mg/dl
12.80
(5.16–25.15)
12.02
(6.33–27.15)
11.48
(6.16–27.30)
11.171
(5.87–26.64)
10.96
(5.60–25.47)
20.002 .82 ,.001
ApoB, g/L 0.91 6 0.23 0.96 6 0.24 0.97 6 0.24 0.98 6 0.25 1.00 6 0.27 0.029 ,.001 ,.001
Data are presented as number (percentage), median and 25th and 75th percentile or mean 6 SD, 3-SNP GRS 5 3-single nucleotide polymorphism.
R 5 Pearson or Spearman correlation, P* 5 unadjusted P-value, P† 5 P-value adjusted for age, sex, diabetes, waist, and body-mass index.
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ter discriminate the different groups both SNPs were used.
The 3-SNP GRS included the number of TG-raising alleles
for each of the selected SNPs carried by each participant.
Scores were given for each TG-raising allele (Table 1). In
GRS 0/6 are those individuals that do not have any of the
variants; in GRS-1/6 are the carriers heterozygous for the
LPL variant; in GRS 2/6 the carriers who are heterozygous
for the APOA5 variants and carriers homozygous for the
LPL variant; in GRS 3/6 are carriers heterozygous for the
LPL as well as the APOA5 variants, whereas GRS $4/6
harbors the rest of the individuals.
Associations between the 3-SNP GRS and lipid param-
eters are displayed in Table S4. Across the GRS categories,
we observed a GRS-dependent increase toward an athero-
genic lipoprotein profile. Plasma apoA-V and apo B levels
were significantly increased, whereas plasma LPL mass
was significantly reduced. Plasma levels of total cholesterolTable 4 Demographic and lifestyle parameters according to the Me
Metabolic risk score #2/5 3/5
N 13,113 4283
Men, n (%) 5529 (42) 2337 (5
Age, y 57.7 6 9.2 61.4 6
Body mass index, kg/m2 25.1 6 3.3 28.1 6
Waist circumference, cm 83.9 6 10.9 94.9 6
Current smoker, n (%) 1466 (11.3) 486 (11
Diabetes mellitus, n (%) 715 (5.8) 754 (21
Systolic blood pressure, mmHg 131 6 17 142 6
Diastolic blood pressure, mmHg 80 6 11 87 6
Mean 3-SNP GRS 2.0 2.1
Data are presented as number (percentage), mean 6 SD. 3-SNP GRS 5 3-sand LDL-C were significantly increased in the higher GRS
categories, whereas HDL-C levels were significantly
decreased (all P , .001). Interestingly, a higher 3-SNP
GRS coincided with the presence of smaller LDL particle
size and greater LDL particle number (P , .001). Inline,
VLDL particle number was significantly increased
(P , .001). Concomitantly HDL particles size was smaller
but no difference in HDL particle number was observed.
Association between the 3-SNP GRS and plasma
TG levels in the complete EPIC cohort
The 3-SNP GRS was evaluated in n 5 20,074 partici-
pants from the EPIC-Norfolk cohort with complete SNP
data available. All 3 SNPs were in Hardy–Weinberg
equilibrium with a probability value of .0.05. Carriership
of the rs3135506 G allele, rs662799 G allele (both in
APOA5), and rs328 C allele (in LPL) was associated withtRS
4/5 5/5 P
2316 362
5) 1304 (56) 200 (55) ,.001
8.9 62.3 6 8.6 63.9 6 8.3 ,.001
3.6 29.2 6 3.7 30.1 6 4.2 ,.001
10.4 98.7 6 10.1 101.5 6 11.8 ,.001
.4) 279 (12.2) 51 (14.1) ,.001
.4) 767 (49.5) 362 (100%) ,.001
17 145 6 16 146 6 17 ,.001
11 88 6 10 88 6 10 ,.001
2.1 2.1
ingle nucleotide polymorphism gene risk score.
Table 5 Distribution lipoproteins according to the MetRS
Metabolic risk score #2/5 3/5 4/5 5/5 R P* P†
Participants, n (%) 13,113 (65.3) 4283 (21.3) 2316 (11.5) 362 (1.8)
Triglyceride, mmol/l 1.30 (0.90–1.60) 2.10 (1.70–2.90) 2.50 (2.10–3.20) 2.70 (2.20–3.40) 0.500 ,.001 ,.001
Total cholesterol, mmol/L 6.01 6 1.10 6.50 6 1.22 6.48 6 1.20 6.30 6 1.19 0.164 ,.001 ,.001
HDL-cholesterol, mmol/L 1.54 6 0.40 1.25 6 0.40 1.05 6 0.25 0.96 6 0.15 20.435 ,.001 ,.001
LDL-cholesterol, mmol/L 3.85 6 1.00 4.19 6 1.04 4.19 6 1.08 4.00 6 1.14 0.129 ,.001 ,.001
Non-HDL-cholesterol, mmol/L 4.45 6 1.09 5.17 6 1.13 5.39 6 1.13 5.33 6 1.17 0.310 ,.001 ,.001
Lipoprotein(a), mg/dl 11.6 (6.2–28.3) 11.2 (6.1–25.2) 11.3 (5.7–25.0) 12.2 (5.51–28.22) 20.022 .006 ,.001
Apo B, g/L 0.94 6 0.23 1.03 6 0.25 1.02 6 0.87 1.00 6 0.26 0.156 ,.001 ,.001
Data are presented as number (percentage), median and 25th and 75th percentile or mean 6 SD.
R 5 Pearson or Spearman correlation, P* 5 unadjusted P-value, P† 5 P-value adjusted for age, sex.
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0.23–0.32] per rs3135506 G allele; 10.29 mmol/l [95%
CI 0.24–0.33] per rs662799 G allele and 10.19 mmol/l
[95% CI 0.15–0.22] per rs328 C allele) (Table 1). The de-
mographic and lifestyle parameters of individuals accord-
ing to the 3-SNP GRS, ranging from 0/6 to $4/6, are
shown in Table 2. In total, 157 participants had a GRS of
0/6, whereas 268 participants had a GRS of $4/6. No sig-
nificant differences between age, sex, body mass index
(BMI), waist circumference, smoking status, presence of
type 2 diabetes mellitus, or blood pressure were observed
between the GRS groups. In Table 3 the distribution of
plasma TG, cholesterol, and apo B levels according to the
3-SNP GRS is displayed. The groups with the highest 3-
SNP GRS score have a less favorable lipid phenotype.
Based on GRS, TG levels ranged from 1.30 (0.90–1.90)
to 2.10 (1.30–3.20) for the lowest (0/6) and the highest
($4/6) 3-SNP GRS, respectively, and were statistically sig-
nificant different (P , .001). Total cholesterol ranged from
6.12 6 1.02 to 6.46 6 1.37 mmol/l, HDL-C from
1.58 6 0.39 to 1.27 6 0.36 mmol/l, LDL-C from
3.87 6 0.92 to 4.11 6 1.14 mmol/L, and Apo B ranged
from 0.91 6 0.23 to 1.00 6 0.27 g/L.
Association of MetRS with plasma TG levels
Next, participants were classified in 4 different cate-
gories according to their MetRS (from #2/5 ie, noTable 6 Risk of future coronary artery disease and stroke per 3-SNP
3- SNP GRS #1/6 2/6
Cases (%)/controls 669 (21%)/2459 3169 (24%)/10,115
HR (95% CI) 1.00 1.14 (1.05–1.23)
P-value .003
HR* (95% CI) 1.00 1.14 (1.05–1.24)
P-value* .002
HR‡ (95% CI) 1.00 1.12 (1.03–1.22)
P-value‡ .010
Hazard ratio (HR) and 95% CI, relative to TG gene score #1, for each 3-SN
*HR adjusted for age, sex, body-mass index, diabetes, and smoking with c
†P value for linearity.
‡HR adjusted for age, sex, body mass index, diabetes, smoking, and LDL-Cmetabolic syndrome to 5/5 being most severely affected).
As expected, significant differences (P , .001) were
observed between the MetRS groups for sex, age, BMI,
waist circumference, smoking status, diabetes mellitus,
and blood pressure (Table 4). Plasma TG levels ranged
from 1.30 (0.90–1.60) to 2.70 (2.20–3.40) mmol/L in the
group with the lowest (#2/5) and the highest (5/5) MetRS
(P , .001). Inline, total cholesterol levels ranged from
6.01 6 1.10 to 6.30 6 1.19 mmol/L, HDL-C ranged
from 1.54 6 0.40 to 0.96 6 0.15 mmol/L, LDL-C ranged
from 3.85 6 1.00 to 4.00 6 1.14 mmol/L in the group
with the lowest (#2/5) and the highest (5/5) group, suggest-
ing the presence of the most unfavorable lipid phenotype in
MetRS group with score 5 (Table 5).
In the small case-control subset, MetRS was associated
with a similar unfavorable lipid profile as observed for the
3-SNP GRS, including significant differences in plasma apo
A-V, apo B, and LPL mass as well as unfavorable changes
in VLDL and particle size and number.
Association of the 3-SNP GRS and MetRS with
CVD risk
We assessed the hazard ratios associated with future
CVD per 3-SNP GRS and MetRS category (Tables 6 and 7,
respectively). Mean follow-up was 16 years. With respect
to the 3-SNP GRS, the unadjusted hazard ratio (HR) for in-
dividuals in the highest category (GRS $4/6) was 1.35GRS category
3/6 $4/6 P†
776 (23%)/2618 77 (29%)/191
1.07 (0.97–1.19) 1.35 (1.07–1.71) .005
.178 .012
1.07 (0.96–1.19) 1.36 (1.07–1.72) ,.001
.207 .011
1.04 (0.93–1.15) 1.35 (1.04–1.74) ,.001
.495 .024
P GRS 5 3-single nucleotide polymorphism gene risk score category.
orresponding P-value.
with corresponding P-value.
Table 7 Risk of future coronary artery disease and stroke per MetRS category
Metabolic risk score #2/5 3/5 4/5 5/5 P†
Cases (%)/controls 2358 (18%)/10,755 1351 (32%)/4283 828 (36%)/2316 154 (43%)/362
HR (95% CI) 1.00 2.02 (1.89–2.16) 2.43 (2.25–2.63) 3.20 (2.72–3.77) ,.001
P-value ,.001 ,.001 ,.001
HR* (95% CI) 1.00 1.49 (1.39–1.60) 1.68 (1.55–1.82) 2.03 (1.73–2.40) ,.001
P-value* .001 ,.001 ,.001
Hazard ratio (HR) and 95% CI, relative to metabolic score #2/5, for each MetRS category.
*HR adjusted for age, sex, and smoking with corresponding P-value.
†P value for linearity.
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score (GRS #1). The multivariable adjusted HR was
14.35 (1.04–1.74, P 5 .024) for those in the highest versus
lowest 3-SNP GRS category. The hazard ratio for individ-
uals in the highest MetRS (5/5) category was 3.20 (2.72–
3.77, P , .001) compared to those in the lowest category
(#2/5). The multivariable adjusted HR was 2.03 (1.73–
2.40, P , .001) for those in the highest versus lowest
category.
The 3-SNP GRS score $ 4/6 was associated with an
increased risk for CVD independent of the presence of
MetRS as the distribution of MetRS amongst each of the
GRS categories was similar (Table 8 and Fig. 1). On the
other hand, the presence of the MetRS predicts CVD
independent of the 3-SNP GRS. Whereas in the partici-
pants with the metabolic syndrome (MetRS $3/5) an
increased CVD risk was observed in all GRS groups
that was not the case in participants without the
metabolic syndrome (MetRS #2/5). CVD HR ranged
from 2.15 (1.13–4.09) to 1.70 (1.02–2.83) for partici-
pants with a GRS of 0/6 and $ 4/6, respectively
(Table 9).
Discussion
Evidence on the causal link between elevated plasma TG
levels and risk of CVD has recently emerged.33–35 It is
however still under debate what determines the contribution
of elevated plasma TG levels to increased CVD risk. Is the
presence of the metabolic syndrome leading to elevated
plasma TG levels or is genetic predisposition also impor-
tant for increased TG-mediated CVD risk?Table 8 Overlap between the MetRS and 3-SNP GRS
3-SNP GRS 0/6 1/6
MetRS
#2/5 119 (75.8%) 2062 (69.4%)
3/5 27 (17.2%) 576 (19.4%)
4/5 10 (6.4%) 287 (9.7%)
5/5 1 (0.6%) 46 (1.5%)
Total 157 (100%) 2971 (100%)
Data are presented as number (percentage). 3-SNP GRS category 5 3-singlePrevious GWAS have discovered multiple genetic loci
associated with plasma TG, which have been recently
confirmed by a large meta-analysis in .100,000 subjects,
detecting 32 loci harboring common variants that contribute
to plasma TG concentration.35 The effect sizes of most of
these loci is small but robust as illustrated by Mendelian
randomization studies.36 Here, we demonstrate in the
EPIC-Norfolk cohort that both a minimal 3-SNP GRS
and MetRS scores were in a stepwise manner associated
with plasma TG levels and future CVD risk. To generate
a GRS we aimed to find the combination of SNPs, resulting
in a 3-SNP GRS by using SNPs in LPL and APOA5, 2 ma-
jor genes with a pivotal role in TG metabolism. There was
an association between the number of TG-raising alleles
and the plasma TG concentration, with a 0.14 mmol/L
per allele change. This effect was independent from other
known risk factors, which influence plasma TG levels
such as age, sex, diabetes, and BMI. No adjustment for
HDL-C was performed because of the high degree of cor-
relation with plasma TG. In Mendelian randomization
studies focused on TG and remnant cholesterol, a similar
observation was found, again suggesting that genetic pre-
disposition results in increased TG levels and CVD risk.36
Our findings are in line with these observations. Elevated
plasma TG, reflected by a 3-SNP GRS $ 4/6, is associated
with a CVD risk increase, with an HR of 1.35 (95% CI:
1.04–1.74; P 5 .024) compared to those with the lowest
3-SNP GRS.
The MetRS is associated with an increase in plasma
TG concentration of 0.72 mmol/L per MetRS point
increase, whereas the multivariate adjusted hazard ratio
(95% CI) for CVD was 2.03 (1.73–2.40; P , .001) for the2/6 3/6 $4/6
8740 (65.8%) 2050 (60.4%) 142 (53.0%)
2790 (21.0%) 816 (24.0%) 74 (27.6%)
1517 (11.4%) 454 (13.4%) 48 (17.9%)
237 (1.8%) 74 (2.2%) 4 (1.5%)
13,284 (100%) 3394 (100%) 268 (100%)
nucleotide polymorphism gene risk score, MetRS 5 metabolic risk score.
Figure 1 Risk of CVD according to a 3-SNP gene risk score (GRS) stratified for metabolic syndrome risk score (MetRS #2 vs $ 3).
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undefined genetic (TG related) factors cannot be
excluded. Further analysis revealed that the 3-SNP
GRS and MetRS both predict TG-mediated CVD risk
and are targeting different subgroups with increased
CVD risk.
The metabolism of TG-rich lipoproteins, HDL-C, and
LDL-C are closely linked. It is therefore interesting to see
that together with elevated plasma TG levels, the 3-SNP
GRS and MetRS, in the case-control subset study, also
coincides with other features of the atherogenic lipid
profile such as increased LDL particle number, smaller
LDL particle size, increased VLDL particle number
reflecting circulating remnant particles, plasma apo A-V
levels, and decreased HDL particle size and plasma
preheparin LPL mass. It is widely accepted that APO
A-V and LPL are pivotal for normal TG homeosta-
sis.16,17,25 Rare mutations, leading to a loss of functionTable 9 Risk of future coronary artery disease and stroke per 3-SNP
3-SNP GRS 0/6 1/6
MetRS
#2/5 1.00 (reference) 1.01 (0.67–1.52)
P-value .97
$3/5 2.15 (1.13–4.09) 1.61 (1.06–2.44)
P-value .020 .025
TG
,1.7 mmol/L 1.00 (reference) 1.02 (0.67–1.54)
P-value .37
$1.7 mmol/L 1.64 (0.86–3.14) 1.34 (0.88–2.03)
P-value .13 .17
Hazard ratio (95% confidence interval) adjusted for age and sex with corresp
score, MetRS 5 metabolic risk score; TG 5 triglyceride.of LPL, lead to a severe hypertriglyceridemic pheno-
type.48 Of note, a higher 3-SNP GRS and MetRS are asso-
ciated with lower preheparin LPL plasma levels.
Interestingly, this also coincided with elevated plasma
apo A-V levels and might explain the observed differences
in lipoprotein particle size and increased plasma TG levels
due to inhibition of LPL activity by apo A-V. However, it
has to be mentioned that the function of apo A-V in lipo-
protein metabolism still remains to be established. These
changes in lipoprotein composition directly influence its
atherogenic properties. Remnant particles may enter the
intima of the artery wall and get trapped, which conse-
quently leads to accumulation of remnant cholesterol re-
sulting in foam cell formation.53
In conclusion, in the present study, we provide evidence
that both the 3-SNP GRS and MetRS scores are signifi-
cantly associated with increased plasma TG concentrations
and an increased risk of CVD.GRS and MetRS categories
2/6 3/6 $4/6
1.12 (0.75–1.67) 1.08 (0.71–1.63) 1.63 (0.98–2.72)
.59 .72 .06
1.81 (1.21–2.71) 1.62 (1.07–2.44) 1.70 (1.02–2.83)
.004 .022 .041
1.12 (0.75–1.67) 1.07 (0.71–1.62) 1.82 (1.06–3.11)
.60 .75 .03
1.52 (1.02–2.28) 1.38 (0.92–2.08) 1.43 (0.88–2.34)
.04 .12 .15
onding P-value. 3-SNP GRS5 3-single nucleotide polymorphism gene risk
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